View in EDS HTML Full Text PDF Full Text

Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.

Saved in:
Bibliographic Details
Title: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.
Authors: Bae S; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee H; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea., Song I; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Kim J; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Lee SR; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Cho S; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea., Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Chung JY; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. jychung@snubh.org.; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea. jychung@snubh.org.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea. jychung@snubh.org.
Source: CNS drugs [CNS Drugs] 2025 Jun; Vol. 39 (6), pp. 583-595. Date of Electronic Publication: 2025 Apr 15.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40234362
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bae+S%22">Bae S</searchLink>; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+H%22">Lee H</searchLink>; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Song+I%22">Song I</searchLink>; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+J%22">Kim J</searchLink>; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+SR%22">Lee SR</searchLink>; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+S%22">Cho S</searchLink>; Department of Clinical Development, Vivozon, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yu+KS%22">Yu KS</searchLink>; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Chung+JY%22">Chung JY</searchLink>; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. jychung@snubh.org.; Department of Health Science and Technology, Seoul National University College of Convergence Science and Technology, Seongnam, Republic of Korea. jychung@snubh.org.; Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Dolmaro 172, Seongnam, Gyeongi, 13605, Republic of Korea. jychung@snubh.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229431220%22">CNS drugs</searchLink> [CNS Drugs] 2025 Jun; Vol. 39 (6), pp. 583-595. <i>Date of Electronic Publication: </i>2025 Apr 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9431220 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1934 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211727047%22">11727047 </searchLink><i>NLM ISO Abbreviation: </i>CNS Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40234362
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-025-01181-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 583
    Titles:
      – TitleFull: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bae S
      – PersonEntity:
          Name:
            NameFull: Lee H
      – PersonEntity:
          Name:
            NameFull: Song I
      – PersonEntity:
          Name:
            NameFull: Kim J
      – PersonEntity:
          Name:
            NameFull: Lee SR
      – PersonEntity:
          Name:
            NameFull: Cho S
      – PersonEntity:
          Name:
            NameFull: Yu KS
      – PersonEntity:
          Name:
            NameFull: Chung JY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2025 Jun
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1934
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: CNS drugs
              Type: main
ResultId 1